Metastatic Colorectal Cancer Treated With FOLFOX + Cetuximab in Long Term Use Protocol - Complete Responses and Acceptable Tolerability Profile - Case Series

International Archives of Medicine
doi 10.3823/1832
Full Text
Abstract

Available in full text

Date
Authors
Publisher

International Medical Publisher (Fundacion de Neurociencias)

Related search

PTEN Status in Advanced Colorectal Cancer Treated With Cetuximab

British Journal of Cancer
Cancer ResearchOncology
2009English

Atypical Metastatic Presentations in Colorectal Cancer: A Case Series

Clinical Colorectal Cancer
OncologyGastroenterology
2014English

Cetuximab in First Line Treatment of Metastatic Colorectal Cancer

Farmeconomia. Health economics and therapeutic pathways
2012English

Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study

Clinical Colorectal Cancer
OncologyGastroenterology
2017English

Long‐term Survival of an Advanced Colorectal Cancer Patient Treated With Regorafenib: Case Report and Literature Review

Clinical Case Reports
Medicine
2019English

Comparison of EORTC Criteria and PERCIST for PET/CT Response Evaluation of Patients With Metastatic Colorectal Cancer Treated With Irinotecan and Cetuximab

Journal of Nuclear Medicine
MedicineNuclear MedicineRadiologyImaging
2013English

Safety and Efficacy of the Addition of Simvastatin to Cetuximab in Previously Treated KRAS Mutant Metastatic Colorectal Cancer Patients

Investigational New Drugs
OncologyPharmacology
2015English

Cetuximab Plus Irinotecan Versus Panitumumab in Patients With Refractory Metastatic Colorectal Cancer in Ontario, Canada

International Journal of Cancer
Cancer ResearchOncology
2017English

Regorafenib Adjusted Dose for Chilean Patients With Chemoresistant Metastatic Colorectal Cancer: A Case Series

ecancermedicalscience
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy